References

Mechanisms of natural killer cell-mediated cellular cytotoxicity

10.1002/jlb.mr0718-269r · 2019 · External reference

Perforin and granzymes: function, dysfunction and human pathology

10.1038/nri3839 · 2015 · External reference

Natural killer cell-based strategies for immunotherapy of cancer

10.1016/bs.apcsb.2022.02.001 · 2022 · External reference

CRISPR screen to identify factors that render tumor cells sensitive or resistant to killing by NK cells

10.1007/978-1-0716-2160-8_19 · 2022 · External reference

Unifying concepts of MHC-dependent natural killer cell education

10.1016/j.it.2011.06.001 · 2011 · External reference

CRISPR enabled precision oncology: from gene editing to tumor microenvironment remodeling

2025 · External reference

A flow cytometry-based whole blood natural killer cell cytotoxicity assay using overnight cytokine activation

10.3389/fimmu.2020.01851 · 2020 · External reference

CD107a degranulation assay to evaluate immune cell antitumor activity

10.1007/978-1-4939-8885-3_7 · 2019 · External reference

iRGD tumor penetrating peptide-modified NK cells exhibit enhanced tumor immune infiltration ability and anti-tumor efficacy

10.2174/0109298665348639250115113650 · 2025 · External reference

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

10.3324/haematol.2013.103085 · 2014 · External reference

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

10.1080/19420862.2021.1950264 · 2021 · External reference

NKG2D and its ligands in cancer

10.1016/j.coi.2018.02.004 · 2018 · External reference

NKG2D ligands-critical targets for cancer immune escape and therapy

10.3389/fimmu.2018.02040 · 2018 · External reference

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

10.1038/nature03884 · 2005 · External reference

The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells

10.3389/fimmu.2013.00508 · 2014 · External reference

Tumor-associated MICA is shed by ADAM proteases

10.1158/0008-5472.can-07-6768 · 2008 · External reference

Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes

10.1158/0008-5472.can-09-1688 · 2010 · External reference

Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy

10.1186/s13046-021-02068-5 · 2021 · External reference

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines

10.1007/s00262-009-0682-y · 2009 · External reference

DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses

10.1093/intimm/dxab085 · 2021 · External reference

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

10.1038/s41423-019-0206-4 · 2019 · External reference

HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition

10.1093/intimm/13.2.193 · 2001 · External reference

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism

10.1172/jci0215564 · 2002 · External reference

Association of HLA class I and class II antigen expression and mortality in uveal melanoma

2001 · External reference

The NKG2A-HLA-E Axis as a novel checkpoint in the tumor microenvironment

10.1158/1078-0432.ccr-19-2095 · 2020 · External reference

Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer

10.3390/vaccines10121993 · 2022 · External reference

Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors

10.2147/itt.s61498 · 2015 · External reference

NK cell metabolism and tumor microenvironment

10.3389/fimmu.2019.02278 · 2019 · External reference

Hepatic tumor microenvironments and effects on NK cell phenotype and function

10.3390/ijms20174131 · 2019 · External reference

Regulatory effects of oncogenes and tumor suppressor genes on tumor immune microenvironment

10.3724/j.pibb.2025.0317 · 2025 · External reference

Mechanisms of resistance to NK cell immunotherapy

10.3390/cancers12040893 · 2020 · External reference

A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling

10.1038/s41422-020-0355-0 · 2020 · External reference

The lytic NK cell immunological synapse and sequential steps in its formation

10.1007/978-0-387-72005-0_23 · 2007 · External reference

The central role of the cytoskeleton in mechanisms and functions of the NK cell immune synapse

10.1111/imr.12107 · 2013 · External reference

Cytotoxic immunological synapses

10.1111/j.0105-2896.2010.00904.x · 2010 · External reference

Navigating barriers: the challenge of directed secretion at the natural killer cell lytic immunological synapse

10.1007/s10875-010-9372-y · 2010 · External reference

Activation of lymphocyte cytolytic machinery: where are we?

10.3389/fimmu.2013.00390 · 2013 · External reference

Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization

10.4049/jimmunol.1000761 · 2010 · External reference

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

10.1136/jitc-2023-008155 · 2024 · External reference

TIGIT affects CAR NK-cell effector function in the solid tumor microenvironment by modulating immune synapse strength

10.1158/2326-6066.cir-24-0919 · 2025 · External reference

Intrinsic resistance of chronic lymphocytic leukemia cells to NK cell-mediated lysis can be overcome in vitro by pharmacological inhibition of Cdc42-induced actin cytoskeleton remodeling

10.3389/fimmu.2021.619069 · 2021 · External reference

Cancer cells suppress NK cell activity by actin-driven polarization of inhibitory ligands to the immunological synapse

10.1073/pnas.2503259122 · 2025 · External reference

Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion

10.1038/nchembio.1388 · 2014 · External reference

Collagen mineralization decreases NK cell-mediated cytotoxicity of breast cancer cells via increased glycocalyx thickness

10.1002/adma.202311505 · 2024 · External reference

A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells

10.1006/cimm.1997.1085 · 1997 · External reference

A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity

10.1186/s13046-023-02840-9 · 2023 · External reference

Immunoengineering can overcome the glycocalyx Armour of cancer cells

10.1038/s41563-024-01808-0 · 2024 · External reference

Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction

10.1186/s12885-025-15108-6 · 2025 · External reference

Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells

10.1016/j.canlet.2015.06.029 · 2015 · External reference

Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1

10.3389/fonc.2014.00245 · 2014 · External reference

PIEZO1-mediated mechanosensing governs NK-cell killing efficiency and infiltration in three-dimensional matrices

10.1002/eji.202350693 · 2024 · External reference

Mechanical regulation of the cytotoxic activity of natural killer cells

10.1021/acsbiomaterials.0c01121 · 2021 · External reference

Natural killer cell cytotoxicity and its regulation by inhibitory receptors

10.1111/imm.12921 · 2018 · External reference

Building tolerance by dismantling synapses: inhibitory receptor signaling in natural killer cells

10.1111/imr.12014 · 2013 · External reference

Molecular regulation of the plasma membrane-proximal cellular steps involved in NK cell cytolytic function

10.1242/jcs.240424 · 2020 · External reference

Lytic granules, secretory lysosomes and disease

10.1016/s0952-7915(03)00113-4 · 2003 · External reference

Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B

10.1074/jbc.m410915200 · 2005 · External reference

Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis

10.1083/jcb.200210158 · 2003 · External reference

Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells

10.1084/jem.188.12.2375 · 1998 · External reference

CD107a as a functional marker for the identification of natural killer cell activity

10.1016/j.jim.2004.08.008 · 2004 · External reference

ESCRT-mediated membrane remodeling in cancer immune evasion and resistance to immunotherapy: mechanisms, therapeutic vulnerabilities, and translational implications

10.1016/j.intimp.2026.117007 · 2026 · External reference

CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity

10.1038/s41467-022-29469-0 · 2022 · External reference

Overview of serpin B9 and its roles in cancer (review)

10.3892/or.2021.8141 · 2021 · External reference

Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion?

10.1016/j.lungcan.2012.01.017 · 2012 · External reference

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

10.1080/2162402x.2022.2139074 · 2022 · External reference

The biological function of Serpinb9 and Serpinb9-based therapy

2024 · External reference

Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer

10.3390/ijms21103726 · 2020 · External reference

Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy

10.1016/j.drup.2004.11.002 · 2004 · External reference

A central role for bid in granzyme B-induced apoptosis

10.1074/jbc.m410985200 · 2005 · External reference

Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition

10.1074/jbc.m008444200 · 2001 · External reference

Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway

10.1074/jbc.m009038200 · 2001 · External reference

BCL-2 protein family: attractive targets for cancer therapy

10.1007/s10495-022-01780-7 · 2023 · External reference

Targeting BCL-2 regulated apoptosis in cancer

10.1098/rsob.180002 · 2018 · External reference

Bcl-2 Antiapoptotic family proteins and chemoresistance in cancer

10.1016/bs.acr.2017.11.001 · 2018 · External reference

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis

10.1016/j.cell.2022.03.030 · 2022 · External reference

Single-cell profiling reveals functional heterogeneity and serial killing in human peripheral and ex vivo-generated CD34+ progenitor-derived natural killer cells

10.1002/adbi.202200207 · 2023 · External reference

NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing

10.1084/jem.20181454 · 2019 · External reference

The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity

10.1016/j.celrep.2024.115156 · 2025 · External reference

Locked and loaded: mechanisms regulating natural killer cell lytic granule biogenesis and release

10.3389/fimmu.2022.871106 · 2022 · External reference

Lytic granule exocytosis at immune synapses: lessons from neuronal synapses

10.3389/fimmu.2023.1177670 · 2023 · External reference

Remodeling of secretory lysosomes during education tunes functional potential in NK cells

10.1038/s41467-019-08384-x · 2019 · External reference

Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells

10.1182/blood-2015-03-632273 · 2015 · External reference

Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time

10.1084/jem.20140964 · 2015 · External reference

NK cell detachment from target cells is regulated by successful cytotoxicity and influences cytokine production

10.1038/s41423-019-0277-2 · 2020 · External reference

Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells

10.1083/jcb.201712085 · 2018 · External reference

Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy

10.1186/s12967-024-05033-w · 2024 · External reference

Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells

10.3389/fimmu.2018.02517 · 2018 · External reference

NK cell exhaustion in the tumor microenvironment

10.3389/fimmu.2023.1303605 · 2023 · External reference

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

10.1038/s41392-020-00348-8 · 2020 · External reference

The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity

10.1002/ijc.34389 · 2022 · External reference

C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer

10.1038/s41467-024-54355-2 · 2024 · External reference

Measuring trogocytosis between ovarian tumor and natural killer cells

10.1016/j.xpro.2022.101425 · 2022 · External reference

Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand

10.1073/pnas.1300140110 · 2013 · External reference

Beyond PD-1/PD-L1: new immune checkpoints and therapeutic combinations in cancer immunotherapy

10.1002/mdb2.70018 · 2026 · External reference

Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and Hyporesponsiveness of NK cells in patients with myeloma

10.1158/1078-0432.ccr-16-1108 · 2016 · External reference

First-in-human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors

10.1158/1078-0432.ccr-24-1991 · 2025 · External reference

Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer

10.1200/jco.2009.25.4847 · 2010 · External reference

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

10.1007/s10637-017-0536-y · 2018 · External reference

IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion

10.1158/1078-0432.ccr-18-3468 · 2019 · External reference

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

10.1136/jitc-2020-002193 · 2021 · External reference

Randomized phase 2 trial of Lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the Effikir trial

10.1182/blood.v130.suppl_1.889.889 · 2017 · External reference

INTERLINK-1: a phase III, randomized, placebo-controlled study of Monalizumab plus Cetuximab in recurrent/metastatic head and neck squamous cell carcinoma

10.1158/1078-0432.ccr-25-0073 · 2025 · External reference

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

10.1182/blood-2011-06-360552 · 2012 · External reference

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): an open-label, randomised, phase 3 trial

10.1016/s1470-2045(21)00342-9 · 2021 · External reference

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study

10.1016/s1470-2045(21)00216-3 · 2021 · External reference

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

10.1158/1078-0432.ccr-11-1347 · 2011 · External reference

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

10.1080/14653240802301872 · 2008 · External reference

Bempegaldesleukin plus Nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results

10.1200/jco.23.00172 · 2023 · External reference

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

10.1080/10428194.2022.2095623 · 2022 · External reference

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

10.1038/s41591-025-03640-8 · 2025 · External reference

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

10.1016/s0140-6736(24)02462-0 · 2025 · External reference